Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: Results from the Medical Data Vision claims database

Morita, Akimichi; Kotowsky, Nirali; Gao, Ran; Shimizu, Reiko; Okubo, Yukari

doi:10.1111/1346-8138.16022

Cited by 39 publications

(103 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been suggested that there may be a female preponderance in GPP; however, the extent of this varies by geographical region and between ethnicities. A study in 102 patients from Malaysia reported a 2:1 ratio of GPP in females versus males; a study of 74 patients in the US reported a 1.03:1 ratio; and in a study of over 700 patients in Japan, 51.5% were female [ 9 , 10 , 14 ]. Findings from a recent inpatient database of 1516 people with GPP in Japan reported that 56% were male, and a registry in Western Japan observed that 52% of 102 GPP cases were male [ 15 , 16 ].…”

Section: Disease Characteristics Of Gppmentioning

confidence: 99%

“…There was a slight female preponderance in patients with GPP (51.5%) compared with those with plaque psoriasis, in which a minority of patients were female (38.7%). Patients with GPP were more likely to have comorbidities than patients with plaque psoriasis; these comorbidities included hypertension, peptic ulcer disease, osteoporosis, type 2 diabetes, gout, psoriatic arthritis, chronic obstructive pulmonary disease, obesity, asthma, insomnia, interstitial pneumonia, thyroid disorders, and other forms of psoriasis [ 14 ]. These findings suggested that patients with GPP in Japan had a higher disease burden than those with psoriasis vulgaris [ 37 ].…”

Section: Adding Evidence To the Understanding Of Gpp Disease Characteristics And Prevalencementioning

confidence: 99%

See 1 more Smart Citation

The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis

2022

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a rare disease that has only recently benefited from a consistent definition and clinical coding standard. A lack of disease awareness combined with clinical similarities to other types of psoriasis have historically complicated the diagnosis of GPP. It is now clear that GPP requires a differential diagnosis from psoriasis vulgaris (plaque psoriasis), and better understanding of the genetic characteristics underlying GPP may improve the accuracy of diagnoses in the future. GPP can present at any age but is most common in the fifth decade of life. There appears to be a female preponderance in GPP, although there is notable variability in prevalence by geographical region and between ethnicities. GPP is potentially life-threatening, associated with several serious complications, and may require emergency treatment, particularly for complications arising from systemic inflammation. As with many rare diseases, there are inherent challenges to understanding the epidemiology of GPP. In addition to small patient numbers, estimating the prevalence of rare diseases is further complicated by studies that use non-standardized methodologies and that are conducted in different populations. These complications in data gathering have led to marked variability in GPP case estimates by geographical region and between ethnicities. There is ongoing research into disease characteristics, and insights into regional measures of prevalence are essential to increasing our understanding of GPP. Graphical abstract

show abstract

Section: Disease Characteristics Of Gppmentioning

confidence: 99%

Section: Adding Evidence To the Understanding Of Gpp Disease Characteristics And Prevalencementioning

confidence: 99%

The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis

2022

View full text Add to dashboard Cite

show abstract

“…Like moderate-to-severe psoriasis, GPP is associated with an increased occurrence of comorbidities compared to the general population. 4 Comorbidities that have been reported in GPP include obesity, hypertension, hyperlipidemia, diabetes, uveitis, 4–7 cholestasis, 8 joint involvement, 4–7 , 9 , 10 allergic rhinoconjunctivitis and peptic ulcer disease. 4 , 7 …”

Section: Introductionmentioning

confidence: 99%

Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study

Löfvendahl¹,

Norlin²,

Schmitt‐Egenolf³

2022

PTT

View full text Add to dashboard Cite

Background Generalized pustular psoriasis (GPP), which can occur with or without psoriasis vulgaris (PV), is a severe form of pustular psoriasis with potentially life-threatening symptoms. GPP is also associated with several comorbidities, which further adds to the burden of disease. This study investigates the economic burden of disease in patients with GPP. Methods All-cause and GPP-specific healthcare resource use (inpatient stays, physician visits and drug use), as well as associated costs, were compared for year 2015 between GPP patients (n = 914) and two matched control groups representing the general population (n = 4047) and patients with PV but no GPP (n = 2556). Information on resource use for 2015 was obtained from the Swedish National Patient Register and Swedish Prescribed Drug Register, respectively. Results All-cause inpatient stays, physician visits, and use of psoriasis-related drugs were significantly more common among GPP patients compared to both control groups. This difference was reflected in total direct cost for GPP patients (5062 euros/year) which was 3.1 and 1.8 times higher (p < 0.001) compared to the general population and PV controls, respectively. For GPP patients, the share of total cost was 22% for all-cause physician outpatient visits and 40% for all-cause inpatient stays. However, only 6.3% and 11.3% of these costs, respectively, were due to GPP-specific problems. Psoriasis-related drugs constituted 27% of total costs for GPP patients of which a large fraction (86%) was represented by biologics. Conclusion This study demonstrates a higher economic burden for GPP patients compared to both the general population and patients with PV, with inpatient visits and use of biologic drugs as major cost driving factors. Only fractions of the costs for physician visits and inpatient stays were attributable to specific GPP problems, indicating a higher economic burden of GPP-consequences and complications.

show abstract

“…Patients with GPP have a higher burden of illness than those with plaque psoriasis [30]. Important complications of acute phase GPP, some of which can be induced by drugs used to treat this disease (e.g.…”

Section: Burden Of Diseasementioning

confidence: 99%

“…A recent retrospective database analysis conducted in Japan showed that, compared with patients with plaque psoriasis (N = 27,773), patients with GPP (N = 718) were more likely to experience comorbidities and to be prescribed antibiotics and psychiatric medication, and required more healthcare resource utilization and longer hospital stays [30]. Not surprisingly, GPP has a notable impact on a patient's QoL, although data quantifying this impact are lacking.…”

Section: Burden Of Diseasementioning

confidence: 99%

Generalized pustular psoriasis: current management status and unmet medical needs in Japan

Komine

Morita

2021

Expert Review of Clinical Immunology

Self Cite

View full text Add to dashboard Cite

Introduction: Generalized pustular psoriasis (GPP) is a rare, inflammatory skin disease characterized by recurrent flares of pustulation accompanied by systemic symptoms that can be life-threatening. The clinical and humanistic burden of GPP in Japan is high, and it is a designated intractable disease. We reviewed clinical evidence and guidelines for GPP treatment in Japan to identify unmet needs and assess data supporting the development and use of new targeted therapies. Areas covered: Using specific search terms in PubMed and Embase, with additional back-referencing, we retrieved literature related to GPP in Japan focusing on clinical and pathogenic characteristics, diagnosis, and treatment. Expert opinion: Although there are approved systemic therapies for GPP in Japan, all present uncertainties in terms of safety and efficacy. Clinical evidence supporting their use comes mostly from studies in patients with mild or moderate disease, and their effectiveness in treating acute phase GPP is unknown. The interleukin-36 pathway appears to be central to GPP pathogenesis. New therapies targeting this pathway show promise in patients presenting with acute phase GPP. The rarity and intermittent course of GPP make it challenging to recruit sufficient patients for trials and robustly investigate the efficacy and safety of these agents to treat GPP.

show abstract

Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: Results from the Medical Data Vision claims database

Cited by 39 publications

References 24 publications

The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis

The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis

Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study

Generalized pustular psoriasis: current management status and unmet medical needs in Japan

Contact Info

Product

Resources

About